Tabula Rasa Healthcare Inc. (NASDAQ:TRHC) had its price target hoisted by equities research analysts at Chardan Capital from $19.50 to $21.00 in a research report issued to clients and investors on Tuesday. The firm currently has a “buy” rating on the stock. Chardan Capital’s price target suggests a potential upside of 41.32% from the stock’s previous close.

Other research analysts have also recently issued research reports about the stock. Stifel Nicolaus lowered their price target on shares of Tabula Rasa Healthcare from $19.00 to $16.00 and set a “buy” rating for the company in a report on Tuesday, May 2nd. UBS AG reissued a “buy” rating and issued a $17.00 price target (down previously from $18.00) on shares of Tabula Rasa Healthcare in a report on Thursday, May 25th. Finally, Zacks Investment Research raised shares of Tabula Rasa Healthcare from a “sell” rating to a “hold” rating in a report on Tuesday, May 16th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $17.50.

Tabula Rasa Healthcare (NASDAQ:TRHC) opened at 14.86 on Tuesday. Tabula Rasa Healthcare has a 12-month low of $10.39 and a 12-month high of $16.85. The stock’s 50 day moving average price is $14.64 and its 200-day moving average price is $14.00. The stock’s market capitalization is $255.86 million.

Tabula Rasa Healthcare (NASDAQ:TRHC) last announced its quarterly earnings results on Monday, August 7th. The company reported $0.06 EPS for the quarter, hitting analysts’ consensus estimates of $0.06. The business had revenue of $29.70 million for the quarter, compared to the consensus estimate of $27.84 million. The business’s revenue for the quarter was up 32.6% compared to the same quarter last year. Analysts expect that Tabula Rasa Healthcare will post $0.41 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Tabula Rasa Healthcare Inc. (TRHC) PT Raised to $21.00 at Chardan Capital” was reported by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/08/08/tabula-rasa-healthcare-inc-trhc-pt-raised-to-21-00-at-chardan-capital.html.

In related news, insider Orsula V. Knowlton sold 8,000 shares of the business’s stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $11.94, for a total value of $95,520.00. Following the sale, the insider now directly owns 919,407 shares of the company’s stock, valued at approximately $10,977,719.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Glen R. Bressner acquired 7,500 shares of the business’s stock in a transaction that occurred on Thursday, May 18th. The stock was bought at an average cost of $11.96 per share, for a total transaction of $89,700.00. Following the completion of the transaction, the director now directly owns 18,256 shares in the company, valued at approximately $218,341.76. The disclosure for this purchase can be found here. Insiders sold a total of 46,759 shares of company stock valued at $634,444 in the last three months. 45.80% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of the stock. Wellington Management Group LLP boosted its stake in shares of Tabula Rasa Healthcare by 37.2% in the first quarter. Wellington Management Group LLP now owns 782,142 shares of the company’s stock valued at $10,544,000 after buying an additional 212,164 shares during the period. Hood River Capital Management LLC boosted its stake in shares of Tabula Rasa Healthcare by 30.1% in the first quarter. Hood River Capital Management LLC now owns 767,501 shares of the company’s stock valued at $10,346,000 after buying an additional 177,774 shares during the period. Sio Capital Management LLC acquired a new stake in shares of Tabula Rasa Healthcare during the third quarter valued at approximately $7,303,000. Cortina Asset Management LLC boosted its stake in shares of Tabula Rasa Healthcare by 16.9% in the fourth quarter. Cortina Asset Management LLC now owns 440,685 shares of the company’s stock valued at $6,601,000 after buying an additional 63,627 shares during the period. Finally, Monashee Investment Management LLC acquired a new stake in shares of Tabula Rasa Healthcare during the third quarter valued at approximately $4,296,000. 24.99% of the stock is currently owned by institutional investors and hedge funds.

About Tabula Rasa Healthcare

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Analyst Recommendations for Tabula Rasa Healthcare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.